Anzeige
Mehr »
Login
Samstag, 24.02.2024 Börsentäglich über 12.000 News von 683 internationalen Medien
Nurexone Biologic: Fallen nächste Woche alle Rekorde?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJH8 | ISIN: FR001400K4B1 | Ticker-Symbol: 2E40
Stuttgart
23.02.24
14:27 Uhr
2,685 Euro
+0,005
+0,19 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHAXIAM THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
PHAXIAM THERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,6153,07012:58

Aktuelle News zur PHAXIAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer1
DiPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market341PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq...
► Artikel lesen
19.01.PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer2
18.01.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024320Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
03.01.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - December 31, 20233
06.12.23Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - November 30, 20234
16.11.23PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer2
14.11.23Erytech Pharma reports Q3 results5
14.11.23Phaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023650Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in...
► Artikel lesen
07.11.23Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 20232
25.10.23PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer1
24.10.23Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus500Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France)...
► Artikel lesen
23.10.23Phaxiam Therapeutics S.A.: TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a "Buy" recommendation509Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial...
► Artikel lesen
23.10.23Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital _September 30, 20232
11.10.23PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer3
09.10.23Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains452PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM's phagogram, first CE-marked Phage Susceptibility Test...
► Artikel lesen
05.10.23PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer4
05.10.23PHAXIAM Therapeutics regains Nasdaq compliance2
04.10.23Phaxiam Therapeutics S.A.: PHAXIAM Receives Compliance Notice from Nasdaq423PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has...
► Artikel lesen
03.10.23Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration580PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in...
► Artikel lesen
Seite:  Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1